Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasm Metastasis × Mercaptopurine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Neoplasms 2 Burkitt Lymphoma 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1 Leukemia, Biphenotypic, Acute 1 Glioblastoma 1

Interventions

pembrolizumab 40 Nivolumab 21 Gemcitabine 20 Paclitaxel 17 Cyclophosphamide 17 Capecitabine 16 fludarabine 11 aldesleukin 11 Ipilimumab 11 Trastuzumab 10 Docetaxel 10 130-nm albumin-bound paclitaxel 10 Interleukin-2 8 Bevacizumab 8 Albumin-Bound Paclitaxel 8 Radiosurgery 7 Cisplatin 7 Biopsy 7 fludarabine phosphate 6 Temozolomide 6 Specimen Handling 6 Irinotecan 6 Fluorouracil 6 Cetuximab 6 Carboplatin 6 avelumab 5 Radiotherapy 5 Pemetrexed 5 Oxaliplatin 5 Magnetic Resonance Spectroscopy 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05276284 2026-01-14

TEMPLE

Rigshospitalet, Denmark

Phase 1/2 Completed

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡